Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemiaEytan M. Stein, Martin S. Tallman, Richard M. Stone et al.|Blood|2017Cited by 1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AMLCourtney D. DiNardo, Hagop M. Kantarjian, Eytan M. Stein et al.|New England Journal of Medicine|2018Cited by 1.4k
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohortLaurence Albigès, Fabrice Barlési, Stéphanie Foulon et al.|Nature Cancer|2020Cited by 119